UHRF1 and melanoma: Although at a significance level of 5%, no statistically significant differences were found in the expression of epigenetic regulators following vemurafenib treatment; however, miR-221 and UHRF1 (binds hemimethylated DNA and recruits DNMT1) were among the most differentially expressed genes, which were described as biomarkers of nevi/melanoma [53] and regulators of melanocytic differentiation [54], respectively (Figure S1).